Doug Ingram, Sarepta CEO
Sarepta won't need FDA adcomm, boosting Duchenne gene therapy's odds
On its quest to get the first gene therapy for Duchenne muscular dystrophy approved by the FDA, Sarepta won’t have to face an FDA advisory …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
